Jiangxi Synergy Pharmaceutical Co Ltd Working Capital to Net Assets Ratio
Jiangxi Synergy Pharmaceutical Co Ltd working capital to net assets ratio. Jiangxi Synergy Pharmaceutical Co Ltd (300636) has a Working Capital to Net Assets ratio of 27.1% as of March 2026. Working capital of CN¥645.88 Million (current assets of CN¥1.43 Billion minus current liabilities of CN¥787.92 Million) is measured against net assets of CN¥2.38 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check 300636 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Jiangxi Synergy Pharmaceutical Co Ltd (2012–2025)
Working capital to net assets ratio of Jiangxi Synergy Pharmaceutical Co Ltd from 2012 to 2025. This chart shows how Jiangxi Synergy Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of March 2026, the ratio stands at 27.1%, reflecting working capital of CN¥645.88 Million against net assets of CN¥2.38 Billion CNY. See 300636 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Jiangxi Synergy Pharmaceutical Co Ltd Working Capital to Net Assets Ratio by Year (2012–2025)
Jiangxi Synergy Pharmaceutical Co Ltd working capital to net assets ratio by year from 2012 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Jiangxi Synergy Pharmaceutical Co Ltd from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Jiangxi Synergy Pharmaceutical Co Ltd assets under control.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 33.6% | CN¥794.81 Million | CN¥2.37 Billion | CN¥1.46 Billion | CN¥666.92 Million | ▲ +10.0 pp |
| 2024 | 23.6% | CN¥545.19 Million | CN¥2.31 Billion | CN¥1.05 Billion | CN¥505.84 Million | ▲ +1.4 pp |
| 2023 | 22.2% | CN¥495.27 Million | CN¥2.23 Billion | CN¥1.20 Billion | CN¥701.71 Million | ▲ +8.4 pp |
| 2022 | 13.9% | CN¥182.91 Million | CN¥1.32 Billion | CN¥757.95 Million | CN¥575.04 Million | ▼ -18.0 pp |
| 2021 | 31.9% | CN¥282.89 Million | CN¥888.11 Million | CN¥643.56 Million | CN¥360.67 Million | ▼ -18.0 pp |
| 2020 | 49.9% | CN¥407.09 Million | CN¥816.50 Million | CN¥665.20 Million | CN¥258.11 Million | ▲ +22.5 pp |
| 2019 | 27.3% | CN¥192.95 Million | CN¥706.31 Million | CN¥381.01 Million | CN¥188.07 Million | ▲ +4.6 pp |
| 2018 | 22.7% | CN¥149.44 Million | CN¥658.16 Million | CN¥292.32 Million | CN¥142.88 Million | ▼ -35.4 pp |
| 2017 | 58.1% | CN¥370.05 Million | CN¥637.10 Million | CN¥433.42 Million | CN¥63.37 Million | ▲ +17.0 pp |
| 2016 | 41.1% | CN¥125.11 Million | CN¥304.66 Million | CN¥213.53 Million | CN¥88.42 Million | ▲ +17.9 pp |
| 2015 | 23.2% | CN¥57.26 Million | CN¥246.66 Million | CN¥147.49 Million | CN¥90.22 Million | ▲ +36.7 pp |
| 2014 | -13.5% | CN¥-15.94 Million | CN¥118.02 Million | CN¥116.34 Million | CN¥132.28 Million | ▲ +19.9 pp |
| 2013 | -33.4% | CN¥-26.34 Million | CN¥78.82 Million | CN¥106.80 Million | CN¥133.14 Million | ▲ +78.3 pp |
| 2012 | -111.8% | CN¥-50.87 Million | CN¥45.51 Million | CN¥78.95 Million | CN¥129.81 Million | — |